UNIQURE N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.92 USD | -2.96% |
|
+4.90% | -27.33% |
| May. 08 | Mizuho Adjusts uniQure's Price Target to $6 From $7, Keeps Neutral Rating | MT |
| May. 07 | UniQure N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Presentation Operator MessageOperator (Operator)Hello, and welcome to the uniQure N.V. EGM 202...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Companyâs lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntingtonâs disease is in Phase I/II clinical study.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
4.568
EUR
Average target price
19.31
EUR
Spread / Average Target
+322.79%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -27.33% | 239M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- QURE Stock
- News uniQure N.V.
- Transcript : uniQure N.V. - Shareholder/Analyst Call